← Back to Search

Other

CB-103 for Osteosarcoma

Phase 1 & 2

Waitlist Available

Led By Elena Garalda, MD, PhD

Research Sponsored by Cellestia Biotech AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trial is testing a new drug, CB-103, to see if it is safe and effective. So far, it seems to be working well.

Eligible Conditions

Osteosarcoma
Adenoid Cystic Carcinoma
Colorectal Cancer
Breast Cancer
Non-Hodgkin's Lymphoma
Glomangiosarcoma
Liver Cancer
Acute Lymphoblastic Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose Limiting Toxicity (DLT)

Secondary outcome measures

Overall Response Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: CB-103Experimental Treatment1 Intervention

CB-103 capsules will be administered orally in treatment cycles of 28-days each.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cellestia Biotech AGLead Sponsor

2 Previous Clinical Trials

36 Total Patients Enrolled

Elena Garalda, MD, PhDPrincipal InvestigatorVall d'Hebron University Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this research been previously documented?

"Presently, two ongoing clinical trials for the drug CB-103 are being run in three cities across seven countries. Cellestia Biotech AG sponsored the first study which included 200 patients and concluded Phase 1 & 2 of its clinical trial process back in 2017. No further tests have been conducted since then."

Answered by AI

How many participants are enrolled in this clinical research project?

"This clinical trial necessitates 200 eligible patients across multiple sites, including Sarcoma Oncology Research Center in Santa Monica and MD Anderson in Houston."

Answered by AI

What are the projected results of this clinical test?

"Cellestia Biotech AG, the study sponsor, has identified Dose Limiting Toxicity (DLT) as the primary outcome that will be monitored for up to 12 months. Furthermore, this clinical trial will track preliminary anti-tumor efficacy through Overall Response Rates of each tumor type; elimination half-life and Time to Cmax via pharmacokinetic analysis will also constitute secondary outcomes."

Answered by AI

Is there any capacity for additional participants in this research effort?

"Affirmative. The information found on clinicaltrials.gov clearly shows that this trial is actively seeking individuals to participate. It was first listed on December 5th 2017 and last updated January 6th 2022, with a goal of gathering 200 patients from 3 different sites."

Answered by AI

How has the efficacy of CB-103 been explored in past research endeavors?

"Currently, 2 trials testing CB-103 are ongoing. Neither of them has advanced to Phase 3 yet. Primarily situated in Amsterdam and Massachusetts, 35 different sites are running clinical studies on this drug."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

2017. "Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03422679.